Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 342

1.

Paroxetine shifts imipramine metabolism.

Albers LJ, Reist C, Helmeste D, Vu R, Tang SW.

Psychiatry Res. 1996 Jan 31;59(3):189-96.

PMID:
8930024
2.

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.

Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD.

Clin Pharmacol Ther. 2003 Mar;73(3):170-7.

PMID:
12621382
3.

The effect of sertraline on the pharmacokinetics of desipramine and imipramine.

Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ.

Clin Pharmacol Ther. 1997 Aug;62(2):145-56.

PMID:
9284850
4.

Serotonin syndrome: case report and review of the literature.

Weiner AL, Tilden FF Jr, McKay CA Jr.

Conn Med. 1997 Nov;61(11):717-21.

PMID:
9419960
5.

Antidepressant-like effects in various mice strains in the tail suspension test.

Ripoll N, David DJ, Dailly E, Hasco√ęt M, Bourin M.

Behav Brain Res. 2003 Aug 14;143(2):193-200.

PMID:
12900045
6.

Tricyclic-resistant depression: treatment resistance or inadequate treatment?

Lydiard RB.

J Clin Psychiatry. 1985 Oct;46(10):412-7. Review.

PMID:
3900051
7.

Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada.

Lapierre Y, Bentkover J, Schainbaum S, Manners S.

Can J Psychiatry. 1995 Sep;40(7):370-7.

PMID:
8548716
8.

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.

Ereshefsky L, Riesenman C, Lam YW.

Clin Pharmacokinet. 1995;29 Suppl 1:10-8; discussion 18-9. Review.

PMID:
8846618
9.

Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.

Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, Chung M.

J Clin Psychopharmacol. 1997 Aug;17(4):284-91.

PMID:
9241008
10.

Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination?

Levitt AJ, Joffe RT, Kamil R, McIntyre R.

J Clin Psychiatry. 1999 Sep;60(9):613-6.

PMID:
10520980
11.

Thioridazine interferences with imipramine metabolism and measurement.

Maynard GL, Soni P.

Ther Drug Monit. 1996 Dec;18(6):729-31.

PMID:
8946674
12.

Managing rapid metabolizers of antidepressants.

Kraus RP, Diaz P, McEachran A.

Depress Anxiety. 1996-1997;4(6):320-7.

PMID:
9166660
13.
14.

The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor.

Nemeroff CB.

Pharmacotherapy. 1994 Mar-Apr;14(2):127-38. Review.

PMID:
8197030
15.

Genetics in pharmacokinetics?

Hartter S.

Am J Psychiatry. 2004 Jul;161(7):1308-9; author reply 1309. No abstract available.

PMID:
15229072
16.

Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.

Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E.

Br J Clin Pharmacol. 1997 Mar;43(3):315-8.

17.

Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients.

Leucht S, Hackl HJ, Steimer W, Angersbach D, Zimmer R.

Psychopharmacology (Berl). 2000 Jan;147(4):378-83.

PMID:
10672631
18.

Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.

Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, Kalow W.

J Clin Psychopharmacol. 1998 Jun;18(3):198-207.

PMID:
9617978
19.

Drug-drug interactions.

Preskorn SH.

J Clin Psychiatry. 1996 May;57(5):223-7. No abstract available.

PMID:
8626354
20.

Economic evaluation of paroxetine and imipramine in depressed outpatients.

Melton ST, Kirkwood CK, Farrar TW, Brink DD, Carroll NV.

Psychopharmacol Bull. 1997;33(1):93-100.

PMID:
9133757

Supplemental Content

Support Center